TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SSY Group ( (HK:2005) ) just unveiled an update.
SSY Group Limited has announced that its product, Finerenone, has received approval from the National Medical Products Administration of China for registration as a bulk drug for market preparations. This approval marks the second such endorsement for entities within China, highlighting the company’s progress in expanding its pharmaceutical offerings. Finerenone is designed to aid adult patients with chronic kidney disease linked to type 2 diabetes, aiming to mitigate risks such as a decline in kidney function, end-stage renal disease, cardiovascular death, and heart failure hospitalization. This development is expected to enhance SSY Group’s market position and provide significant benefits to patients and stakeholders.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company is engaged in creating treatments for chronic conditions, with a notable emphasis on medications for kidney disease and diabetes-related complications.
Average Trading Volume: 11,101,615
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.15B
Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.